Dr. Samuel O. Anim, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 19
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
ND license 11958 · MN license 54658 -
Pediatrics Physician
MI license 4301087288 -
Student in an Organized Health Care Education/Training Program
MI license 4301087288
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uh Cleveland Medical Center Cleveland, OH
Medical groups
- University Hospitals Medical Group Inc (2,294 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 19
- Services billed
- 47
- Patients’ average age
- 37
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 31 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Fargo, ND | 276 |
| Hydromorphone Hcl Other prescribers in Fargo, ND | 89 |
| Methadone Hcl Other prescribers in Fargo, ND | 51 |
| Cyclobenzaprine Hcl Other prescribers in Fargo, ND | 50 |
| Hydroxyurea Other prescribers in Fargo, ND | 49 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Fargo, ND | 44 |
| Eliquis (apixaban) Other prescribers in Fargo, ND | 32 |
| Ibuprofen Other prescribers in Fargo, ND | 31 |
| Tizanidine Hcl Other prescribers in Fargo, ND | 25 |
| Buprenorphine-Naloxone (buprenorphine hcl/naloxone hcl) Other prescribers in Fargo, ND | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $1,488 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,364 |
|---|---|
| Novo Nordisk Inc | $125 |
| Travel and Lodging | $999 |
|---|---|
| Food and Beverage | $490 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Nov 14, 2025 | Travel and Lodging VIJOICE · Oncology · travel to Dallas, TX · in-kind | $789 |
| Novartis Pharmaceuticals Corporation Nov 14, 2025 | Travel and Lodging VIJOICE · Oncology · travel to Dallas, TX · in-kind | $210 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $36,884 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy
Agios Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.